| P50 | author | Drosos E. Karageorgopoulos | Q54297342 |
| | Matthew E. Falagas | Q87082633 |
| P2093 | author name string | Giannoula S Tansarli | |
| P2860 | cites work | Candida urinary tract infections--treatment. | Q51175452 |
| | Candidemia in intensive care unit patients: Risk factors for mortality | Q58840028 |
| | Amphotericin B nephrotoxicity | Q68501495 |
| | Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans | Q74523209 |
| | Amphotericin B deoxycholate: no significant advantage of a 24 h over a 6 h infusion schedule | Q80405521 |
| | Candidaemia: incidence, risk factors, characteristics and outcomes in immunocompetent critically ill patients | Q83205199 |
| | Echinocandins: a new class of antifungal | Q28201851 |
| | Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial | Q28359772 |
| | Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system | Q33908389 |
| | Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate | Q34113525 |
| | History of the development of azole derivatives | Q34293222 |
| | New antifungal agents-treatment standards are beginning to grow old. | Q34508876 |
| | Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. | Q35136891 |
| | Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate | Q35244959 |
| | Randomized, double-blind trial of 1- versus 4-hour amphotericin B infusion durations | Q35565314 |
| | Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B | Q35843584 |
| | Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis | Q36042366 |
| | Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies | Q36506378 |
| | Caspofungin for the treatment of fungal infections: a systematic review of randomized controlled trials | Q36701175 |
| | Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ | Q37164067 |
| | Treatment of cryptococcal meningitis in resource limited settings | Q37545277 |
| | Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis | Q38052888 |
| | Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate. | Q40441148 |
| | Continuous infusion of amphotericin B: preliminary experience at Faculdade de Medicina da Fundação ABC. | Q40491015 |
| | Brief report: practicability and safety of amphotericin B deoxycholate as continuous infusion in neutropenic patients with hematological malignancies | Q40501860 |
| | Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. | Q40528020 |
| | Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients | Q40776303 |
| | High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial | Q43678311 |
| | Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. | Q44064682 |
| | Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in allogenic stem cell transplantation | Q44166780 |
| | Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study | Q44396642 |
| | The solubility ceiling: a rationale for continuous infusion amphotericin B therapy? | Q44573526 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | amphotericin B | Q412223 |
| | meta-analysis | Q815382 |
| P304 | page(s) | e77075 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis | |
| P478 | volume | 8 | |